Evidence map›Paper›PMID 27222134›Full record

ArticlePathology oncology research : POR2016

P21 and p27 Immunoexpression in Upper Urinary Tract Urothelial Carcinomas.

Banu Sarsik, Basak Doganavsargil, Adnan Simsir, Ayse Yazici, Burcin Pehlivanoglu, Cag Cal, Sait Sen

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications.International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Banu SarsikDepartment of Pathology, Ege University Faculty of Medicine, Bornova, 35100, Izmir, Turkey. bsarsik@yahoo.com.
Basak DoganavsargilDepartment of Pathology, Ege University Faculty of Medicine, Bornova, 35100, Izmir, Turkey.
Adnan SimsirDepartment of Urology, Ege University Faculty of Medicine, Izmir, Turkey.
Ayse YaziciDepartment of Pathology, Mugla University Education and Research Hospital, Mugla,, Turkey.
Burcin PehlivanogluDepartment of Pathology, Adiyaman University Training and Research Hospital, Adiyaman, Turkey.
Cag CalDepartment of Urology, Ege University Faculty of Medicine, Izmir, Turkey.
Sait SenDepartment of Pathology, Ege University Faculty of Medicine, Bornova, 35100, Izmir, Turkey.
Ege University · TRAdıyaman University · TRMuğla University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

p21 and p27 are members of cyclin-dependent kinase family, which function as tumor suppressors and they are involved in development and progression of several malignancies. We investigated their expression in upper urinary tract urothelial carcinoma (UUTUC). Radical nephroureterectomy materials of 34 patients were assessed by immunohistochemistry to evaluate expression of p21 and p27 in UUTUC. Results were correlated with various clinicopathological variables as age, gender, tumor grade and stage, tumor architecture, multifocality, subsequent bladder carcinoma development and clinical outcome.p21 and p27 expression was observed in 52.9 % (n = 18) and 88.2 % (n = 30), respectively. A total of 21 tumors (61.7 %) showed either total loss of p21 expression (n = 16, 47 %) or lower expression (n = 5, 14.7 %). No correlation was found between p21 expression and clinicopathologic variables. Cases showing total loss or lower p27 expression (11.7 % and <25.6 %, respectively) (n = 19, 55.8 %) constituted 67.6 % (n = 23) of the cases totally. This loss or lower p27 expression correlated with a shorter overall survival in both univariate and multivariate analysis (p = 0.039 and p = 0.037, respectively). None of the noninvasive tumors (papillary and nodular tumors) showed loss of p27 (p = 0.016) while 33.3 % of invasive ones showed p27 loss. Noninvasive tumor architecture also correlated with subsequent bladder carcinoma development (p = 0.032) while invasive tumor architecture correlated with advanced stage (T3 and T4) (p = 0.003). p27 is widely expressed in UUTUC, while p21 expression is observed in half of the cases. Loss of p27 expression correlated with tumor architecture and overall survival in UUTUC. However, further research is needed to assess their role in UUTUC.

Indexed as

AgedCyclin-Dependent Kinase Inhibitor p21Disease ProgressionFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedPrognosisProliferating Cell Nuclear AntigenUrinary Bladder NeoplasmsUrinary TractUrologic NeoplasmsCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21p27 antigenProliferating Cell Nuclear AntigenCylin-dependent kinase inhibitorsp21p27PrognosisUpper tract urothelial carcinomaUrinary tract

Identifiers

PMID27222134
OpenAlexW2401764290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.